-
JANSSEN PHARMACEUTICALS, INC. et al v. SANDOZ INC. et al DC CAFC
- 2:13-cv-06929
- D.N.J.
- Judge: Claire C. Cecchi
+1
- Filed: 11/14/2013
- Closed: 01/26/2016
- Latest Docket Entry: 03/24/2020
- PACER
3
Plaintiffs
6
Defendants
2
Accused
Products
2
Patents-in-Suit
804
Days in
Litigation
-
JANSSEN PHARMACEUTICALS, INC. et al v. SANDOZ INC. et al DC CAFC
- 2:13-cv-06929
- D.N.J.
- Judge: Claire C. Cecchi
+1
- Filed: 11/14/2013
- Closed: 01/26/2016
- Latest Docket Entry: 03/24/2020
- PACER
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A crystalline Form A of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K<sub>α</sub> radiation at 15.1±0.2, 16.0±0.2,
view more
|
Enforceable and Valid
Entry 232 Entry 209 |
2 |
The crystalline Form A of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride according to claim 1 exhibiting at least X-ray lines (2-theta values) in a powder diffraction when measured using Cu K<sub>α</sub> radiation at
view more
|
Enforceable and Valid
Entry 232 Entry 209 |
3 |
The crystalline Form A of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride according to claim 1 exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K<sub>α</sub> radiation essentially
view more
|
Enforceable and Valid
Entry 232 Entry 209 |
25 |
A solid pharmaceutical composition comprising, as an active ingredient, a crystalline Form A of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride exhibiting at least X-ray lines (2-theta values) in a powder diffraction
view more
|
Enforceable and Valid
Entry 232 Entry 209 |
Claim # | Claim Text | Outcome |
---|---|---|
8 |
A method of treating a mammal suffering from pain, said method comprising administering to said mammal an effective analgesic amount of a 1-phenyl-3-dimethylaminopropane compound corresponding to formula I<chemistry id="CHEM-US-00044"
view more
|
Enforceable and Valid
Entry 232 Entry 209 |
61 |
<?insert-start id="INS-S-00062" date="20070424" ?>61. (−)-(<i>1R,2R</i>)-<i>3</i>-(<i>3</i>-<i>dimethylamino</i>-<i>1</i>-<i>ethyl</i>-<i>2</i>-<i>methylpropyl</i>)-<i>phenol hydrochloride </i>(−<i>21</i>).<?insert-end id="INS-S-00062" ?>
|
Enforceable and Valid
Entry 232 Entry 209 |
117 |
<?insert-start id="INS-S-00118" date="20070424" ?>117. A method according to claim 8, wherein the compound is (−)-(<i>1R,2R</i>)-<i>3</i>-(<i>3</i>-<i>dimethylamino</i>-<i>1</i>-<i>ethyl</i>-<i>2</i>-<i>methylpropyl</i>)-<i>phenol hydrochloride
view more
|
Enforceable and Valid
Entry 232 Entry 209 |
147 |
<?insert-start id="INS-S-00148" date="20070424" ?>147. A pharmaceutically acceptable salt of (−)-(<i>1R,2R</i>)-<i>3R</i>-(<i>3</i>-<i>dimethylamino</i>-<i>1</i>-<i>ethyl</i>-<i>2</i>-<i>methylpropyl</i>)-<i>phenol.<?insert-end id="INS-S-00148"
view more
|
Enforceable and Valid
Entry 232 Entry 209 |
-
Infringement
Roxane Laboratories Incorporated
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
20641850 mg, 100 mg tapentadol hydrochloride tablets 50 mg, 75 mg, 100 mg tapentadol hydrochloride tabletsGeneric 50 mg, 75 mg, 100 mg tapentadol hydrochloride tabletsRoxane’s ANDA Nos. 205057 | US 7,994,364 B2 |
1, 2, 3, 25
|
Infringement
Entry 232Entry 209 |
20641850 mg, 100 mg tapentadol hydrochloride tablets 50 mg, 75 mg, 100 mg tapentadol hydrochloride tabletsGeneric 50 mg, 75 mg, 100 mg tapentadol hydrochloride tabletsRoxane’s ANDA Nos. 205057 | US RE39,593 E1 |
8, 61, 117, 147
|
Infringement
Entry 232Entry 209 |
Sandoz Inc.
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
50 mg, 100 mg tapentadol hydrochloride tablets 50 mg, 75 mg, 100 mg tapentadol hydrochloride tablets | US 7,994,364 B2 |
1, 2, 3, 25
|
Infringement
Entry 232
|
50 mg, 100 mg tapentadol hydrochloride tablets 50 mg, 75 mg, 100 mg tapentadol hydrochloride tablets | US RE39,593 E1 |
8, 61, 117, 147
|
Infringement
Entry 232
|